Biotech projects worth Rs 3,000 crore are likely to be announced during the annual BioAsia conference, which begins here from February 21. These projects have been proposed in Hyderabad
Sri Bio Integrated Discovery Centre, a stem cell banking and a research facility by Pacific Hospitals and Trans-Scell Biologies, and a large cancer research centre and hospital in collaboration with French government by Renaissance and Biogenesis and Renaissance Cancer Hospital & Research Centre would announce their plans next week, major industries minister J Geeta Reddy said here today.
Apart from new investments, Lonza Knowledge Centre by Swiss-based Lonza, which has already acquired land for its research and manufacturing facility in the Hyderabad Genome Valley and Lepakshi Knowledge Hub in Anantapur would be launched during the four-day international event, said the minister.
Addressing a press conference in connection with the BioAsia, the global business forum supported by the Andhra Pradesh government, the minister said delegates from 24 countries, including China and Malaysia, were taking part.
A CEO conclave and three tracks of conference — namely MediAsia, AgriAsia and HealthAsia, an international trade show with 90 participant companies and around 1,000 B2B meetings between Indian and overseas counterparts among others have been lined up. Lifescience companies, contract research organisations, contract research and manufacturing services (CRAMs), investors, technology developers, institutes among others will participate.
This year’s International Genome Valley Excellence awards will be presented to chairman of Dr Reddy’s Laboratories Limited Anji Reddy and the Beijing Institute of Genomics, Chinese Academy of Sciences, by chief minister N Kiran Kumar Reddy. The chief minister will formally inaugurate the conference on February 22.
For the first time Pharmexcil, the Government of India’s pharmaceutical export promotion council, has also joined the meet by sponsoring the visit of over 30 foreign delegates from 18 counties to promote biopharma products from India.
More From This Section
Hyderabad accounts for about 40 per cent of the country's biopharma exports, according to PV Appaji, executive director of Pharmexcil. He said the pharmaceutical exports this year were expected to register around 17 per cent CAGR. The biopharma segment, which includes vaccine manufacturing, is also looking up.
B Sam Bob, principal secretary, state industries and commerce department, said about 200 companies were currently operating out of the three phases of Genome Valley project.